Mechanisms Underlying Metastatic Pancreatic Cancer

被引:6
|
作者
Pitarresi, Jason R. [1 ,2 ]
Rustgi, Anil K. [3 ]
机构
[1] Univ Penn, Dept Med, Div Gastroenterol, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Columbia Univ, Irving Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA
关键词
Pancreatic cancer; Epithelial-mesenchymal transition (EMT); Cellular plasticity; Metastasis; Metastatic organotropism; TO-MESENCHYMAL TRANSITION; DUCTAL ADENOCARCINOMA; EPITHELIAL PLASTICITY; CELLS; EMT; PROGRESSION; EXPRESSION; KRAS(G12D); INHIBITOR; COOPERATE;
D O I
10.1007/978-3-030-22254-3_1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma is an overwhelming fatal disease that often presents with overt metastases and ultimately causes the majority of cancer-associated deaths. The mechanisms underlying the metastatic cascade are complex, and research in recent years has begun to provide insights into the underlying drivers of this phenomenon. It has become clear that cancer cells, in particular pancreatic cancer cells, possess properties of plasticity involving bidirectional transition between epithelial and mesenchymal identities. Furthermore, recent work has begun to establish that there are distinct hybrid states between purely epithelial and purely mesenchymal states that cancer cells may reside, in order to thrive at different stages of carcinogenesis. We discuss how this plasticity is important for different phases of the metastatic cascade, from delamination to colonization, and how different epithelial-mesenchymal states may affect metastatic organotropism. In this review, we summarize the current understanding of pancreatic cancer cell plasticity and metastasis, and highlight current model systems that can be used to study these phenomena.
引用
收藏
页码:3 / 10
页数:8
相关论文
共 50 条
  • [1] Metastatic pancreatic cancer: Mechanisms and detection
    Chen, Xiangling
    Liu, Fangfang
    Xue, Qingping
    Weng, Xiechuan
    Xu, Fan
    ONCOLOGY REPORTS, 2021, 46 (05)
  • [2] Risk factors for pancreatic cancer: underlying mechanisms and potential targets
    Kolodecik, Thomas
    Shugrue, Christine
    Ashat, Munish
    Thrower, Edwin C.
    FRONTIERS IN PHYSIOLOGY, 2014, 4
  • [3] Mechanisms Underlying the Beneficial Synergistic Effects of Phytochemicals On Pancreatic Cancer
    Edderkaoui, Mouad
    Zheng, Ling
    Hui, Hongxiang
    Li, Gang
    Go, Vay L.
    Pandol, Stephen J.
    GASTROENTEROLOGY, 2009, 136 (05) : A330 - A330
  • [4] Risk factors for pancreatic cancer: underlying mechanisms and potential targets
    Pandol, Stephen J.
    FRONTIERS IN PHYSIOLOGY, 2014, 5
  • [5] Treatment and underlying mechanisms of pancreatic cancer cachexia (PANCAX study)
    Khanuja, Jasleen
    Gresham, Gillian
    Osipov, Arsen
    Tuli, Richard
    Hendifar, Andrew Eugene
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [6] Vitamins in Pancreatic Cancer: A Review of Underlying Mechanisms and Future Applications
    Davis-Yadley, Ashley H.
    Malafa, Mokenge P.
    ADVANCES IN NUTRITION, 2015, 6 (06) : 774 - 802
  • [7] Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer
    Garajova, Ingrid
    Le Large, Tessa Y.
    Frampton, Adam E.
    Rolfo, Christian
    Voortman, Johannes
    Giovannetti, Elisa
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [8] The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer
    Xiong, Guangbing
    Feng, Mengyu
    Yang, Gang
    Zheng, Suli
    Song, Xujun
    Cao, Zhe
    You, Lei
    Zheng, Lianfang
    Hu, Ya
    Zhang, Taiping
    Zhao, Yupei
    CANCER LETTERS, 2017, 397 : 94 - 102
  • [9] Mechanisms Underlying Gemcitabine Resistance in Pancreatic Cancer and Sensitisation by the iMiD™ Lenalidomide
    Fryer, Rosemary A.
    Barlett, Blake
    Galustian, Christine
    Dalgleish, Angus G.
    ANTICANCER RESEARCH, 2011, 31 (11) : 3747 - 3756
  • [10] Metastatic pancreatic cancer
    Kulke M.H.
    Current Treatment Options in Oncology, 2002, 3 (6) : 449 - 457